A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets

Acta Neuropathol Commun. 2021 Jan 11;9(1):14. doi: 10.1186/s40478-020-01107-0.

Abstract

An adequate understanding of the relationships between radiographic and genomic features in diffuse intrinsic pontine glioma (DIPG) is essential, especially in the absence of universal biopsy, to further characterize the molecular heterogeneity of this disease and determine which patients are most likely to respond to biologically-driven therapies. Here, a radiogenomics analytic approach was applied to a cohort of 28 patients with DIPG. Tumor size and imaging characteristics from all available serial MRIs were evaluated by a neuro-radiologist, and patients were divided into three radiographic response groups (partial response [PR], stable disease [SD], progressive disease [PD]) based on MRI within 2 months of radiotherapy (RT) completion. Whole genome and RNA sequencing were performed on autopsy tumor specimens. We report several key, therapeutically-relevant findings: (1) Certain radiologic features on first and subsequent post-RT MRIs are associated with worse overall survival, including PD following irradiation as well as present, new, and/or increasing peripheral ring enhancement, necrosis, and diffusion restriction. (2) Upregulation of EMT-related genes and distant tumor spread at autopsy are observed in a subset of DIPG patients who exhibit poorer radiographic response to irradiation and/or higher likelihood of harboring H3F3A mutations, suggesting possible benefit of upfront craniospinal irradiation. (3) Additional genetic aberrations were identified, including DYNC1LI1 mutations in a subgroup of patients with PR on post-RT MRI; further investigation into potential roles in DIPG tumorigenesis and/or treatment sensitivity is necessary. (4) Whereas most DIPG tumors have an immunologically "cold" microenvironment, there appears to be a subset which harbor a more inflammatory genomic profile and/or higher mutational burden, with a trend toward improved overall survival and more favorable radiographic response to irradiation, in whom immunotherapy should be considered. This study has begun elucidating relationships between post-RT radiographic response with DIPG molecular profiles, revealing radiogenomically distinct subgroups with unique clinical trajectories and therapeutic targets.

Keywords: DIPG; Molecular subgrouping; Overall survival; Radiogenomics; Serial MR imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use
  • Brain Stem Neoplasms / diagnostic imaging*
  • Brain Stem Neoplasms / genetics*
  • Brain Stem Neoplasms / pathology
  • Brain Stem Neoplasms / radiotherapy
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Cytoplasmic Dyneins / genetics
  • DNA Modification Methylases / genetics
  • DNA Repair Enzymes / genetics
  • Diffuse Intrinsic Pontine Glioma / diagnostic imaging*
  • Diffuse Intrinsic Pontine Glioma / genetics*
  • Diffuse Intrinsic Pontine Glioma / pathology
  • Diffuse Intrinsic Pontine Glioma / radiotherapy
  • Disease Progression
  • Epithelial-Mesenchymal Transition / genetics
  • ErbB Receptors / genetics
  • Female
  • Histones / genetics
  • Humans
  • Imaging Genomics*
  • Magnetic Resonance Imaging
  • Male
  • Pilot Projects
  • Proton Therapy
  • Radiation-Sensitizing Agents / therapeutic use
  • Radiotherapy
  • Sequence Analysis, RNA
  • Survival Rate
  • Tumor Microenvironment / genetics
  • Tumor Suppressor Proteins / genetics
  • Whole Genome Sequencing
  • Young Adult

Substances

  • Antineoplastic Agents
  • H3-3A protein, human
  • H3C2 protein, human
  • Histones
  • Radiation-Sensitizing Agents
  • Tumor Suppressor Proteins
  • DNA Modification Methylases
  • MGMT protein, human
  • EGFR protein, human
  • ErbB Receptors
  • DYNC1LI1 protein, human
  • Cytoplasmic Dyneins
  • DNA Repair Enzymes